In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aptalis Holdings Inc.

Division of Allergan PLC
www.aptalispharma.com

Latest From Aptalis Holdings Inc.

CHMP Positive On Safinamide, First New Parkinson’s Therapy In 10 Years

Newron expects partner Zambon to start marketing safinamide in the first half of 2015 in Europe, and to resubmit it soon for U.S. approval. Other positive CHMP opinions this month include Orexigen’s obesity therapy Mysimba and Durata’s antibiotic Xydalba.

BioPharmaceutical Europe

"Sunshine" Database Picks Up Most Vetted-of-Vetted Doctors: FDA Advisory Committee Members

How broad is the Sunshine payment list? Even the highly vetted members on FDA’s advisory committees show up as recipients of payments from healthcare companies during the last three months of 2013. And because payments to medical professionals are the qualification for showing up on the list, there is some interesting data on some policy experts and former FDA officials.

BioPharmaceutical Advertising, Marketing & Sales

Deal Watch: Pfizer/AstraZeneca Lead Pack Of Takeover Efforts

Pfizer’s new, increased offer for AstraZeneca on May 2 was rejected swiftly by the U.K.’s second-largest pharmaceutical company. But other companies’ acquisitive strategies have been more successful this week, with Forest announcing plans to acquire Furiex, Bristol buying out one-asset biotech iPierian, and Endo nabbing the privately owned Mexican specialty company, Somar.

BioPharmaceutical Europe

Biopharma Dealmaking Quarterly Statistics, Q1 2014

Biopharma financing totaled $9.8 billion, a 53% increase over Q4 2013. Twenty-two M&As were completed with a combined potential value reaching $31.3 billion, and there were 103 biopharma alliances totaling $1.9 billion in potential pre-commercialization value, down 30% from the previous quarter.

BioPharmaceutical Deals
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register